

Adalimumab

[Dosage](#) [Administration advice](#) [Off-label use](#) [Practice points](#) [Products](#)

A-Z drug finder

Drug name				
A	B	C	D	E
F	G	H	I	J
K	L	M	N	O
P	Q	R	S	T
U	V	W	X	Y-Z

Brand name

Adalimumab

TNF-alpha antagonist

For more detailed drug information, see [Adalimumab](#) in the AMH.

Dosage – Adalimumab

Seek paediatric specialist advice relevant to indication (eg rheumatologist, gastroenterologist, dermatologist or ophthalmologist).

Juvenile idiopathic arthritis

Use with [methotrexate](#), or alone if methotrexate not tolerated.

If no response after the initial 12 weeks, consider stopping adalimumab treatment.

Polyarticular

2–18 years

10–30 kg, SC 20 mg once every 2 weeks.

>30 kg, SC 40 mg once every 2 weeks.

Enthesitis-related

6–18 years

10–30 kg, SC 20 mg once every 2 weeks.

>30 kg, SC 40 mg once every 2 weeks.

Refractory non-infectious anterior uveitis

Use with [methotrexate](#).

2–18 years

<30 kg, SC 20 mg once every 2 weeks.

>30 kg, SC 40 mg once every 2 weeks.

Moderate-to-severe Crohn's disease

6–18 years and <40 kg

SC, 80 mg on day 0, then 40 mg on day 14, then 20 mg once every 2 weeks starting on day 28.

Consider giving the maintenance dose once a week if disease flares or response is poor.

6–18 years and >40 kg

SC, 160 mg on day 0 (or 80 mg on each of day 0 and day 1), then 80 mg on day 14, then 40 mg once every 2 weeks starting on day 28.

Consider increasing the maintenance dose to 40 mg once a week or 80 mg once every 2 weeks if disease flares or response is poor.

Severe chronic plaque psoriasis

If no response after the initial 16 weeks, consider stopping adalimumab treatment.

4–18 years

<40 kg, SC 20 mg once a week for the first 2 doses, then once every 2 weeks.

>40 kg, SC 40 mg once a week for the first 2 doses, then once every 2 weeks.

Active moderate-to-severe hidradenitis suppurativa

If no response after the initial 12 weeks, consider stopping adalimumab treatment.

12–18 years, SC 80 mg then, starting 1 week after the first dose, 40 mg once every 2 weeks.

Consider increasing the maintenance dose to 40 mg once a week or 80 mg once every 2 weeks if response is poor.

Administration advice

For information about parenteral administration, see the [Royal Children's Hospital Paediatric Injectable Guidelines](#).

Off-label use

Product information does not include doses for uveitis in children.

Practice points

- antibodies to adalimumab can develop during treatment, which is associated with reduced efficacy; the incidence is:
 - lower when also treated with methotrexate
 - about 10% higher in children with JIA than in adults with rheumatoid arthritis
 - lowest in children with Crohn's disease compared to other indications
- observe the usual precautions, eg vaccination requirements, and monitoring required for an immunosuppressant
- little information about adalimumab in children aged <4 years with polyarticular JIA, in children with psoriasis aged <9 years (particularly those <6 years), or in those with enthesitis-related arthritis; use in hidradenitis suppurativa is extrapolated from adult studies

Products

[Search for Adalimumab on the PBS](#)

inj, 20 mg, 0.2 mL (syringe), 2, *Humira*, PBS-A^{1,2}/PBS-S100³

inj, 20 mg, 0.4 mL (syringe), 2, *Amgevita*^a, PBS-A^{1,2}/PBS-S100³

inj, 40 mg, 0.4 mL (syringe), 2, 6, *Humira*, PBS-A[2]^{1,2,3,4,5}/PBS-A[6]^{1,2}/PBS-S100[2]³

inj, 40 mg, 0.4 mL, 2, 4, 6, *Humira*^b, PBS-A[2]^{1,2,3,4,5}/PBS-A[4]⁶/PBS-A[6]^{1,2,6}/PBS-S100[2]³

inj, 40 mg, 0.8 mL (syringe), 2, *Amgevita*^a, *Hadlima*^a, *Hyrimoz*^a, *Idacio*^a,

PBS-A^{1,2,3,4,5}/PBS-A[6]^{1,2}/PBS-S100³

inj, 40 mg, 0.8 mL, 2, *Amgevita*^{a,b}, *Hadlima*^{a,b}, *Hyrimoz*^{a,b}, *Idacio*^{a,b},

PBS-A^{1,2,3,4,5}/PBS-A[4]⁶/PBS-A[6]^{1,2,6}/PBS-S100³

inj, 80 mg, 0.8 mL (syringe), 1, *Humira*, PBS-A⁵/PBS-A[2]⁶/PBS-A[3]^{1,2,6}

inj, 80 mg, 0.8 mL, 1, *Humira*^b, PBS-A⁵/PBS-A[2]⁶/PBS-A[3]^{1,2,6}

¹ Crohn's disease, see PBS

² ulcerative colitis, see PBS

³ JIA, see PBS

⁴ rheumatoid or psoriatic arthritis; ankylosing spondylitis; see PBS

⁵ severe chronic plaque psoriasis, see PBS

⁶ moderate-severe hidradenitis suppurativa, see PBS

^a biosimilar, see [Prescribing biosimilar products](#) in AMH

^b preloaded injector

[Top of page](#)